Evidence mapPaperPMID 40196019Full record

ReviewFrontiers in nutrition2025

Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases.

Sathish Kumar Perumal, Madan Kumar Arumugam, Natalia A Osna, Karuna Rasineni, Kusum K Kharbanda

Abstract readReview
In one paragraph

Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Dietary Supplementation ofAnimals : an open access journal from MDPI · 2025
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sathish Kumar Perumal *Research Service, Department of Veterans Affairs, Nebraska-Western Iowa Health Care System, Omaha, NE, United States.
Madan Kumar Arumugam *Research Service, Department of Veterans Affairs, Nebraska-Western Iowa Health Care System, Omaha, NE, United States.
Natalia A OsnaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Karuna RasineniDepartment of Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States.
Kusum K KharbandaResearch Service, Department of Veterans Affairs, Nebraska-Western Iowa Health Care System, Omaha, NE, United States.

Funding

The Role of TP-R on Alcohol-Induced Multi-Organ Damage: Liver and HeartP50AA030407 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2023 to 2025
$4.7M
Role of alcohol-induced ghrelin in modulating organ crosstalk to promote the development of fatty liver diseaseR01AA028504 · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2025 to 2025
$339k
BLRD VA I01 BX006064NIAAA NIH HHS P50 AA030407NIAAA NIH HHS R01 AA028504
6 · The paper itself

Abstract

Chronic liver disease is defined by persistent harm to the liver that might result in decreased liver function. The two prevalent chronic liver diseases are alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD). There is ample evidence that the pathogenesis of these two chronic liver diseases is closely linked to gastrointestinal dysfunctions that alters the gut-liver crosstalk. These alterations are mediated through the imbalances in the gut microbiota composition/function that combined with disruption in the gut barrier integrity allows for harmful gut microbes and their toxins to enter the portal circulation and reach the liver to elicit an inflammatory response. This leads to further recruitment of systemic inflammatory cells, such as neutrophils, T-cells, and monocytes into the liver, which perpetuate additional inflammation and the development of progressive liver damage. Many therapeutic modalities, currently used to prevent, attenuate, or treat chronic liver diseases are aimed at modulating gut dysbiosis and improving intestinal barrier function. Betaine is a choline-derived metabolite and a methyl group donor with antioxidant, anti-inflammatory and osmoprotectant properties. Studies have shown that low betaine levels are associated with higher levels of organ damage. There have been several publications demonstrating the role of betaine supplementation in preventing the development of ALD and MASLD. This review explores the protective effects of betaine through its role as a methyl donor and its capacity to regulate the protective gut microbiota and maintain intestinal barrier integrity to prevent the development of these chronic liver diseases. Further studies are needed to enhance our understanding of its therapeutic potential that could pave the way for targeted interventions in the management of not only chronic liver diseases, but other inflammatory bowel diseases or systemic inflammatory conditions.

Indexed as

alcohol-associated liver diseasebetainegut-liver axisgut microbiomeintestinal barrier integritylivermetabolic dysfunction-associated steatotic liver disease

Identifiers

PMID40196019
PMCPMC11973089

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.